en · de · es · fr · pt
handling-notes.peptides1126.com › Wiki › Receptor Mechanism And Pharmacokinetics — Worked Examples

Receptor Mechanism And Pharmacokinetics — Worked Examples

By Editorial Desk · published 2025-09-29 · last reviewed 2025-11-05 · Wiki

bremelanotide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2025-11-05. Numbers and descriptions here follow the published literature rather than marketing material.

Receptor Mechanism And Pharmacokinetics

The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.

After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.

Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.

Background and Receptor Pharmacology

Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.

Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.

Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.

Pt-141 at a glance

PropertyValueNotes
Primary targetMC4RHighest reported functional activity
Peak plasma timeAbout 1 hourSubcutaneous administration
Elimination half-lifeA few hoursActive fragment may extend effect
Main clearance routeProteolytic degradationNot cytochrome-dependent
Typical assayLC-MS/MSPlasma quantification

Bremelanotide Naming and Background

Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.

Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.

Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.

Related pages on this site

Handling Storage and Quality Control

Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.

Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.

Background from the literature

=== Precursor of Others === Arginine is also a precursor for urea, ornithine, and agmatine; is necessary for the synthesis of creatine; and can also be used for the synthesis of polyamines (mainly through ornithine and to a lesser degree through agmatine, citrulline, and glutamate). The presence of asymmetric dimethylarginine (ADMA), a close relative, inhibits the nitric oxide reaction; therefore, ADMA is considered a marker for vascular disease, just as L-arginine is considered a sign of a healthy endothelium. In mammals, arginine can be converted into proline via glutamate-5-semialdehyde and pyrroline-5-carboxylic acid. The conversion of arginine into other amino acids also occurs in bacteria; for example, species of the genus Bacillus can convert arginine into proline or glutamic acid via ornithine. The Solanum alkaloids (from the plant family Solanaceae) and Veratrum alkaloids (genus Veratrum) are synthesized from cholesterol via biosynthesis. Nitrogen is introduced from arginine through transamination. Vargulin is a luciferine formed by shellfish from arginine, tryptophan, and isoleucine, and is used to produce bioluminescence in the form of blue light. During bioluminescence, the reaction of a luciferin with a luciferase generates an energetically excited molecule that emits light. Vargulin is found in the genera Vargula and Cypridina, as well as in certain fish species that consume shellfish and acquire the compound through their diet.

== Clinical significance == Due to the essential role of NADPH in lipid and DNA biosynthesis and the hyperproliferative nature of most cancers, NADK is an attractive target for cancer therapy. Furthermore, NADPH is required for the antioxidant activities of thioredoxin reductase and glutaredoxin. Thionicotinamide and other nicotinamide analogs are potential inhibitors of NADK, and studies show that treatment of colon cancer cells with thionicotinamide suppresses the cytosolic NADPH pool to increase oxidative stress and synergizes with chemotherapy. While the role of NADK in increasing the NADPH pool appears to offer protection against apoptosis, there are also cases where NADK activity appears to potentiate cell death. Genetic studies done in human haploid cell lines indicate that knocking out NADK may protect from certain non-apoptotic stimuli.

== Etymology == Samaale, the last common ancestor of several Somali clans, is generally regarded as the source of the ethnonym Somali. Another theory is that the name is derived from the words soo and maal, which together mean "go" and "milk". This interpretation varies depending on region, with northern Somalis believing it means "camel's milk," and southern Somalis using the transliteration "sa maal", which refers to cow's milk. This is a reference to the pastoralism of the Somali people. Another proposed etymology is that the term Somali is derived from the Arabic ذوو مال, transliterated as dhawu māl and meaning "wealthy", again referring to Somali riches in livestock. The first written reference of the sobriquet Somali dates back to the early 15th century AD during the reign of Ethiopian Emperor Yeshaq I, who had one of his court officials compose a hymn celebrating a military victory over the Sultanate of Ifat. Simur was also an ancient Harari alias for the Somali people.

NAD+ is not approved or licensed for medical use in the UK; there are likely breaches of advertising and medicines rules, and no proof that treatments work. Medical experts say "It's complete nonsense" ... "It's untested and unproven. We don't know anything about its efficacy or long-term safety". A November 2024 study, cited 700 times, claiming that NAD+ levels in lab rats decreased with age was withdrawn after images were found to have been manipulated, and underlying data were not provided to the publishers on request.

Sources: en.wikipedia.org

Further detail

== Animal studies == Because of its significant role in the transportation of organic anion molecules and recent association with multiple illnesses including Alzheimer's disease (AD), the ABCC1 protein has become a potential drug target. In ABBC1 knockout mice, β-amyloid clearance is much lower than in wild-type mice that expressed the gene. Furthermore, in mouse models of AD, treatment with thiethylperazine, a drug that activates ABBC1, increases β-amyloid clearance and decreases in the amount of β-amyloid found in the brains. St. John's wort, a substance containing the chemical hyperforin, has also been shown to have a positive effect on activity levels of ABCC1. In a study of the effects of St. John's wort on APP-tg mice, an extract of St. John's wort that contained decreased levels of hyperforin increased the activity of ABCC1 by 70 percent and led to decreased amounts of β-amyloid in the brain and increased cognitive function in the mice.

=== Internal factors === Internal factors causing necrosis include: trophoneurotic disorders (diseases that occur due to defective nerve action in a part of an organ which results in failure of nutrition); injury and paralysis of nerve cells. Pancreatic enzymes (lipases) are the major cause of fat necrosis. Necrosis can be activated by components of the immune system, such as the complement system; bacterial toxins; activated natural killer cells; and peritoneal macrophages. Pathogen-induced necrosis programs in cells with immunological barriers (intestinal mucosa) may alleviate invasion of pathogens through surfaces affected by inflammation. Toxins and pathogens may cause necrosis; toxins such as snake venoms may inhibit enzymes and cause cell death. Necrotic wounds have also resulted from the stings of Vespa mandarinia. Pathological conditions are characterized by inadequate secretion of cytokines. Nitric oxide (NO) and reactive oxygen species (ROS) are also accompanied by intense necrotic death of cells. A classic example of a necrotic condition is ischemia which leads to a drastic depletion of oxygen, glucose, and other trophic factors and induces massive necrotic death of endothelial cells and non-proliferating cells of surrounding tissues (neurons, cardiomyocytes, renal cells, etc.). Recent cytological data indicates that necrotic death occurs not only during pathological events but it is also a component of some physiological process.

Apart from negative affectivity and disinhibition, research has found "substantial but mixed" associations with the other trait domains, indicating the heterogeneity of the diagnosis, which aligns with the view of BPD as an "index of global personality pathology and severity, which aligns with the original metaphorical use of the term 'borderline' or 'borderland'". It is suggested that it "therefore seems reasonable if the borderline pattern serves as a transitional specifier that eventually is phased out in the coming era".

== Discovery == In a screen for genes involved in apoptosis, Yasumasa Ishida, Tasuku Honjo and colleagues at Kyoto University in 1992 discovered and named PD-1. In 1999, the same group demonstrated that mice where PD-1 was knocked down were prone to autoimmune disease and hence concluded that PD-1 was a negative regulator of immune responses. In 2025, Yasumasa Ishida was part of a group that found that PD-1, together with its extracellular ligand "PD-L1" (the name given to the single gene precursor of both PD-L1 and PD-L2 genes in tetrapod species) and cytoplasmic tail binding phosphatases SHP-1 and SHP-2, and their interaction motifs, are well-conserved in evolution throughout jawed vertebrates (from the level of sharks) (Figure 2). This corroborated partial findings by others.

=== Energy conversion === Photocatalytic water splitting is an artificial photosynthesis process in which water is dissociated into hydrogen (H2) and oxygen (O2), using artificial or natural light. Methods such as photocatalytic water splitting are currently being investigated to produce hydrogen as a clean source of energy. The superior electron mobility and high surface area of graphene oxide sheets suggest it may be implemented as a catalyst that meets the requirements for this process. Specifically, graphene oxide's compositional functional groups of epoxide (-O-) and hydroxide (-OH) allow for more flexible control in the water splitting process. This flexibility can be used to tailor the band gap and band positions that are targeted in photocatalytic water splitting. Recent research experiments have demonstrated that the photocatalytic activity of graphene oxide containing a band gap within the required limits has produced effective splitting results, particularly when used with 40-50% coverage at a 2:1 hydroxide:epoxide ratio. When used in composite materials with CdS (a typical catalyst used in photocatalytic water splitting), graphene oxide nanocomposites have been shown to exhibit increased hydrogen production and quantum efficiency.

Sources: en.wikipedia.org

Background from the literature

2024 Greater Manchester mayoral election: Labour's Andy Burnham secures a third term as Mayor of Greater Manchester with almost two-thirds of the votes cast. The SDLP announces that it will change the way it makes "civil leadership" appointments following the resignation from the party of two Derry City and Strabane District Council councillors over the appointment of Lilian Seenoi-Barr as the authority's next mayor. 5 May – With all votes counted, the results from the local elections in England are: Labour 1,158 (+186), Liberal Democrat 522 (+104), Conservative 515 (−474), Independents and others 228 (+93), Green 181 (+74), Residents' Association 48 (+11), Workers Party of Britain 4 (+4), Reform UK 2 (+2). 6 May – Argentina's president, Javier Milei, tells the BBC he accepts the Falkland Islands are currently "in the hands of the UK", but says his country will get them back through diplomatic channels. John Swinney is confirmed as Leader of the Scottish National Party after being unopposed in the leadership election, and begins his second tenure in the post. 7 May – John Swinney wins the backing of the Scottish Parliament to become Scotland's seventh First Minister, and will be sworn into office the next day. The Green Party's Siân Berry, who was re-elected in the 2024 London Assembly election, is criticised for resigning three days later to hand her seat to Zoë Garbett, who lost in the same election with 5.8% of the vote.

Aerotolerant anaerobes use fermentation to produce ATP. They do not use oxygen, but they can protect themselves from reactive oxygen molecules. In contrast, obligate anaerobes can be harmed by reactive oxygen molecules. There are three categories of anaerobes. Where obligate aerobes require oxygen to grow, obligate anaerobes are damaged by oxygen, aerotolerant organisms cannot use oxygen but tolerate its presence, and facultative anaerobes use oxygen if it is present but can grow without it. Most aerotolerant anaerobes have superoxide dismutase and (non-catalase) peroxidase but do not have catalase. More specifically, they may use a NADH oxidase/NADH peroxidase (NOX/NPR) system or a glutathione peroxidase system. An example of an aerotolerant anaerobe is Cutibacterium acnes.

Later 1987 experiments on the longer-lived isotope 260Lr confirmed lawrencium's trivalency and that it eluted in roughly the same place as erbium, and found that lawrencium's ionic radius was 88.6±0.3 pm, larger than would be expected from simple extrapolation from periodic trends. Later 1988 experiments with more lawrencium atoms refined this to 88.1±0.1 pm and calculated an enthalpy of hydration value of −3685±13 kJ/mol. It was also found that the actinide contraction at the end of the actinides was larger than the analogous lanthanide contraction, with the exception of the last actinide, lawrencium: the cause was speculated to be relativistic effects. It has been speculated that the 7s electrons are relativistically stabilized, so that in reducing conditions, only the 7p1/2 electron would be ionized, leading to the monovalent Lr+ ion. However, all experiments to reduce Lr3+ to Lr2+ or Lr+ in aqueous solution were unsuccessful, similarly to lutetium. On the basis of this, the standard electrode potential of the E°(Lr3+ → Lr+) couple was calculated to be less than −1.56 V, indicating that the existence of Lr+ ions in aqueous solution was unlikely. The upper limit for the E°(Lr3+ → Lr2+) couple was predicted to be −0.44 V: the values for E°(Lr3+ → Lr) and E°(Lr4+ → Lr3+) are predicted to be −2.06 V and +7.9 V. The stability of the group oxidation state in the 6d transition series decreases as RfIV > DbV > SgVI, and lawrencium continues the trend with LrIII being more stable than RfIV.

=== Cardiac === The apelin receptor is expressed early during the embryonic development of the heart, where it regulates the migration of cell progenitors fated to differentiate into cardiomyocytes, the contractile cells of the heart. Its expression is also detected in the cardiomyocytes of the adult where apelin behaves as one of the most potent stimulator of cardiac contractility. Aged apelin knockout mice develop progressive impairment of cardiac contractility. Apelin acts as a mediator of the cardiovascular control, including for blood pressure and blood flow. It is one of the most potent stimulators of cardiac contractility yet identified, and plays a role in cardiac tissue remodeling. Apelin levels are increased in left ventricles of patients with chronic heart failure and also in patients with chronic liver disease.

=== Acute gastroenteritis === A position paper from the ESPGHAN Working Group for Probiotics and Prebiotics, based on systematic reviews and randomized controlled trials, suggested that S. boulardii may be considered as an adjunct to rehydration therapy in the management of acute gastroenteritis in children. The recommendation was classified as strong despite the underlying evidence being rated as low quality.

Sources: en.wikipedia.org

Frequently asked questions

Which receptor mediates the main effect?

MC4R is regarded as the primary mediator on the basis of binding and functional assays. Other subtypes are also engaged, which helps explain flushing and related side effects. The step from receptor activation to reported desire change remains partly inferential.

How long does the compound stay in the body?

Elimination is rapid, with a half-life of a few hours. An active fragment circulates after breakdown, so biological activity may outlast measurable parent drug. This is one reason single-timepoint measurements are limited.

Are drug interactions a concern?

Because breakdown is mainly proteolytic rather than cytochrome-dependent, classic metabolic interactions are less likely. Agents affecting blood pressure could still matter. Formal interaction studies are sparse.

What does the code PT-141 refer to?

PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.

Network